\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationOnline
ProgrammesThe European Cancer Imaging Initiative aims to promote innovation in digital technologies, including Artificial Intelligence, to advance in the fight against cancer. The cornerstone of the initiative is the Cancer Image Europe Infrastructure developed by the Digital Europe project EUCAIM. The platform will make large amounts of cancer images available to European researchers, innovators and clinicians in a privacy-preserving setting, opening the door to the next generation of cancer diagnostics and treatment.
This CONNECT University session will present the Initiative’s milestones and achievements, and delve into EUCAIM’s infrastructure from multiple perspectives. The session will also explore Cancer Image Europe’s approach in working with sensitive health data, as well as current uptake, trends and future horizons for AI-based imaging solutions in cancer.
For more information on the event, the agenda and the connection link please visit the event website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
